When.com Web Search

  1. Ads

    related to: asthma inhaler cost without insurance

Search results

  1. Results From The WOW.Com Content Network
  2. Some drugmakers to cap cost of asthma inhalers at $35 a month

    www.aol.com/news/drugmakers-cap-cost-asthma...

    He also takes albuterol, also from AstraZeneca, for his asthma. Despite having health insurance, Shapland said the cost can balloon to $350 a month — a significant financial burden — depending ...

  3. Boehringer to cut out-of-pocket costs for inhalers to $35 - AOL

    www.aol.com/news/boehringer-cut-pocket-costs...

    (Reuters) - Boehringer Ingelheim will reduce out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma to $35 per month starting June 1, the German drugmaker ...

  4. AstraZeneca to cap US out-of-pocket costs for inhalers at $35 ...

    www.aol.com/news/astrazeneca-cap-us-pocket-costs...

    Boehringer had also said it would cap out-of-pocket costs for its inhaler products for chronic lung disease and asthma to $35 per month, starting June 1. ... including inhalers to treat asthma and ...

  5. WHO/Health Action International Project on Medicine Prices ...

    en.wikipedia.org/wiki/WHO/Health_Action...

    [11]: 189 The WHO/HAI provide the following 5 stages taxonomy of the medicines prices in the supply chain: [5]: 221–222 [11]: 190 Manufacturer's selling price plus insurance and freight: the price charged by the pharmaceutical manufacturer, including the cost of insurance and shipping the medicines to the countries of destination.

  6. AstraZeneca capping COPD, asthma medications at $35 a month - AOL

    www.aol.com/news/astrazeneca-capping-copd-asthma...

    For premium support please call: 800-290-4726 more ways to reach us

  7. Fluticasone furoate/vilanterol - Wikipedia

    en.wikipedia.org/wiki/Fluticasone_furoate/vilanterol

    The FDA label was changed in April 2015, to add an indication for a once-daily treatment of asthma in people aged 18 years of age and older. [3] The exclusivity for a new product ended in May 2016, in the United States, and the exclusivity on the indication for asthma expired on 30 April 2018. [ 11 ]